Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combination therapy improves AIDS-related lymphoma outcome

28.02.2006


Combining aggressive HIV therapy and chemotherapy significantly improves the survival rates of HIV-positive men and women treated for lymphoma, according to a new study. Published in the April 1, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study reveals that combination therapy showed the greatest benefit for HIV patients suffering from aggressive malignant non-Hodgkin’s lymphoma. This benefit was most pronounced in HIV patients without severely impaired immune functions. These so-called "standard risk" patients responded as well to therapy and survived as long as lymphoma patients without HIV.



Lymphomas are cancers of the immune system’s white blood cells. They are treated with chemotherapy, often consisting of a multi-drug regimen using cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). People with HIV, a virus that depletes integral, specialized white cells called CD-4 cells, are at increased risk of developing lymphomas, particularly aggressive, fast-growing non-Hodgkin type lymphomas. These are called "AIDS-related lymphomas" (ARL) and generally have a poorer prognosis than non-HIV-related lymphomas. Highly active antiretroviral therapy (HAART) revolutionized care of HIV-positive men and women. It not only improves laboratory indicators, such as increased CD-4 cells and reduced viral loads, but also significantly improves survival and delays the onset of AIDS and AIDS-related cancers, including lymphomas.

With the lack of study data to show the efficacy of maintaining HIV-positive patients on HAART while they are treated with chemotherapy for ARL, oncologists are hesitant to expose HIV patients to hypothetical drug toxicities related to combining the therapies. Researchers led by Rudolf Weiss, M.D., of Specialist Practice for Hematology, Oncology and Infectious Diseases in Bremen, Germany, treated 72 HIV-patients with ARL divided into high-risk and standard-risk cohorts with combined CHOP and HAART to evaluate the safety and efficacy of the combined regimen.


The investigators found combined therapy improved survival rates for patients with ARL and standard level of risk to rates comparable to those in non-HIV patients with lymphoma treated with CHOP and superior to previously published rates achieved by CHOP alone. For standard-risk ARL patients 79 percent achieved complete remission, and after 47 months of follow-up and study’s end, more than 50 percent of patients survived. Moreover, only 40 percent reported moderate drug toxicity. For high-risk ARL patients, only 29 percent achieved complete remission and median survival was only 7.2 months. Sixty-nine percent reported moderate toxicity.

"The present study showed that our risk-adapted strategy for concomitant administration of HAART with CHOP is effective and safe," the authors concluded.

David Greenberg | EurekAlert!
Further information:
http://www.wiley.com
http://www.interscience.wiley.com/cancer-newsroom

More articles from Studies and Analyses:

nachricht Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland

nachricht Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

When Air is in Short Supply - Shedding light on plant stress reactions when oxygen runs short

23.03.2017 | Life Sciences

Researchers use light to remotely control curvature of plastics

23.03.2017 | Power and Electrical Engineering

Sea ice extent sinks to record lows at both poles

23.03.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>